Skip to Main content Skip to Navigation
New interface
Journal articles

Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183

Abstract : Drug resistance and a dire lack of transmission-blocking antimalarials hamper malaria elimination. Here, we present the pantothenamide MMV693183 as a first-in-class acetyl-CoA synthetase (AcAS) inhibitor to enter preclinical development. Our studies demonstrate attractive drug-like properties and in vivo efficacy in a humanized mouse model of Plasmodium falciparum infection. The compound shows single digit nanomolar in vitro activity against P. falciparum and P. vivax clinical isolates, and potently blocks P. falciparum transmission to Anopheles mosquitoes. Genetic and biochemical studies identify AcAS as the target of the MMV693183-derived antimetabolite, CoA-MMV693183. Pharmacokinetic-pharmacodynamic modelling predict that a single 30 mg oral dose is sufficient to cure a malaria infection in humans. Toxicology studies in rats indicate a > 30-fold safety margin in relation to the predicted human efficacious exposure. In conclusion, MMV693183 represents a promising candidate for further (pre)clinical development with a novel mode of action for treatment of malaria and blocking transmission.
Document type :
Journal articles
Complete list of metadata
Contributor : Benoit Witkowski Connect in order to contact the contributor
Submitted on : Monday, June 20, 2022 - 10:15:30 AM
Last modification on : Friday, November 4, 2022 - 6:54:06 PM


Publication funded by an institution


Distributed under a Creative Commons Attribution 4.0 International License




Laura E de Vries, Patrick a M Jansen, Catalina Barcelo, Justin Munro, Julie M J Verhoef, et al.. Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183. Nature Communications, 2022, 13 (1), pp.2158. ⟨10.1038/s41467-022-29688-5⟩. ⟨pasteur-03699217⟩



Record views


Files downloads